Hypofractionated radiation therapy for invasive breast cancer: From moderate to extreme protocols

Adjuvant irradiation is the standard treatment after breast conservative surgery. Normofractionated regimen with an overall treatment time of 5 to 6 weeks is often considered as a limiting factor for irradiation compliance. In order to answer this issue, moderate and more recently extreme hypofractionated protocols appeared. We report here oncological outcomes and toxicity of hypofractionated breast irradiation. After defining the frame of moderate and extreme hypofractionated breast irradiations based on overall treatment time, patient selection criteria were listed. According to their levels of proof, the results of moderate and extreme hypofractionated breast irradiation were analysed. Overall treatment time for moderate hypofractionated breast irradiation ranged from 3 to 4 weeks, while for extreme hypofractionated breast irradiation, it was less than 1 week. For moderate hypofractionated breast irradiation, whole breast irradiation was currently performed with or without lymph node irradiation. Moderate hypofractionated breast irradiation has proven to be as safe and as efficient as normofractionated breast irradiation with level IA evidence. For extreme hypofractionated breast irradiation, phase III randomized trials confirmed that accelerated partial breast irradiation was non-inferior in terms of local control compared to normofractionated whole breast irradiation (with external beam radiation therapy and multicatheter brachytherapy), with similar acute and late toxicity. While the use of intraoperative breast irradiation remains under debate, new very accelerated partial breast irradiation (overall treatment time not exceeding 2 days) protocols emerged with encouraging results. Accelerated partial breast irradiation is warranted for extreme hypofractionated breast irradiation and is indicated for low-risk breast cancers. Moderate and extreme hypofractionated breast irradiation regimens are validated and can be routinely proposed according to patient selection criteria.     

某设备所致脉冲X射线辐射场测量与防护评价

目的 了解某设备实验条件下不同位置脉冲X射线电离辐射水平，提出适当的防护建议。方法 采用热释光测量方法，分别在设备舱周围不同方向不同距离布放热释光剂量计，累积一定数量脉冲辐射后进行测量；采用电离室型X、γ剂量率仪（FJ-347A）实时测量工作状态下不同距离处电离辐射剂量率水平。依据《电离辐射防护与辐射源安全基本标准》（GB18871—2002）规定的职业照射人员和公众个人剂量限值提出不同工作位辐射防护建议。结果 热释光剂量计累计接收3 000个脉冲辐射，设备舱外壁0.01～8.98 mGy，顶部0.01～15.67 mGy，距外壁1～12 m之间0.01～2.18 mGy，工作位0 mGy。工作状态下，X射线剂量率仪测得距设备舱外侧壁1～20 m之间空气比释动能率范围0.26～16 mGy/h。结论 热释光剂量计、电离室型剂量率仪测量结果基本一致，说明两种方法均可用于脉冲X射线测量；工作状态下设备舱外近距离处辐射剂量率较高，可通过采取防护措施或者限制人员工作量以满足辐射防护要求。     

高剂量CT辐射致家兔脾组织病理变化的初步实验研究

目的初步探讨CT腹部模式常规和非常规扫描次数、高曝光剂量扫描对家兔急性脾组织病理变化的影响。方法将46只大白兔随机分成3组：（1）高曝光剂量CT扫描组36只。采用约为常规剂量2倍的腹部CT扫描模式,对大白兔进行全身扫描,再将其分两大亚组,每组18只。①腹部模式一次性扫描组（一次性扫描组）：CT扫描层厚为2.5mm分别连续扫描3、6、9、12、15和18次,48h后剖杀;②腹部模式重复扫描组（重复扫描组）：CT扫描层厚以5mm分别连续扫描2、4、6、8、10和12次,24h后重复上述扫描,24h后剖杀。（2）常规CT扫描组：5只,采用常规次数和曝光剂量对大白兔进行全身扫描,48h后剖杀。（3）健康对照组：5只。所有实验动物取脾组织作病理分析。结果光镜病理结果：①一次性扫描组：连续扫描6次时出现红髓髓窦略扩张、淤血;连续9-18次扫描后,脾脏出现红髓髓窦扩张、淤血,可见网状组织细胞增生和吞噬含铁血黄素。②重复扫描组：共8次扫描时出现红髓髓窦轻度扩张、淤血,散在中性粒细胞浸润;16-24次扫描后,脾脏出现红髓髓窦扩张、淤血,散在中性粒细胞浸润,间或有组织细胞增生。结论常规脾脏CT扫描是非常安全的;在非常规扫描次数和高曝光剂量下,CT辐射可能会引起家兔急性脾组织的异常病理变化。     

肾综合征出血热地鼠肾细胞Ⅱ型灭活疫苗的安全性、免疫性及其流行病学效果考核

目的：考核HFRS地鼠肾细胞Ⅱ型灭活疫苗的安全性、免疫法及其流行病学效果。方法：采用间接免疫荧光抗体试验（IFA）、微量细胞变性中和试验（MCPENT），检测接种者血中荧光抗体及中和抗体水平；调查接种组与对照组发病情况。结果：以怀宁、广德两县18个村为疫苗观察现场，接种组7499人，对照组7261人，中强反应率为224％（5／223）。3针全程免疫后中和抗体阳转率为63．33％（19／30），荧光抗体阳转率为38.58％（27／70）；接种后1年内接种组无发病，对照组发病3例。结论：该疫苗的安全性较好；有一定水平的免疫应答，但防病效果应进一步观察确证。     

支架术治疗颈动脉狭窄的临床研究

目的　观察支架术治疗颈动脉狭窄的近期疗效 ,探讨临床应用中的相关问题。方法　将临床经颈部B超、脑血管造影确诊的颈动脉狭窄患者 10 8例 ,实施颈动脉支架术 ,15例行预扩张 ,12例后扩张成形 ,9例使用滤器装置 ,围手术期给予抗血小板聚集等治疗。结果　 2例手术失败 ;术后 2例发生脑出血 ,1例脑栓塞 ,1例支架内血栓形成 ,除 1例脑出血死亡外 ,3例治疗后恢复 ;1～ 6个月的随访中 ,10 5例患者无复发。手术并发症发生率低 ,近期疗效满意。结论　颈动脉狭窄段支架术治疗颈动脉狭窄具有可行性 ,近期疗效肯定 ,是临床上有推广潜力的治疗颈动脉狭窄的方法 ,但远期疗效尚需进一步观察。     

低能量血管内激光照射治疗脑损伤的免疫功能变化与研究

本文对49例接受低能全血管内激光照射治（ILIB）的脑损伤病人的免疫功能改变进行研究．研究显示，低能量血管内激光照射疗法可明显改善免疫状态和免疫反应水平，增强免疫功能和机体抗感染能力．     

照射与免疫的时间间隔对抗体形成的影响及其辐射剂量效应

本实验观察了0. 25、0. 5、1. 0、2. 0、3. 0和4. 0Gy全身照射后3至6 h羊红细胞(SRBC)免疫对小鼠脾脏抗体形成细胞(PFC)的影响。结果发现,各剂量照射后,免疫与照射的时间间隔较长者,辐射对PFC反应的抑制显著加深。照射后3及6h免疫,脾脏PFC反应均随照射剂量的增加而降低。照射后3h免疫时,PFC反应的D_(37)值为4. 13Gy;照射后6h免疫时,PFC反应的D_(37)值为1. 74Gy。     

The Chemical Protecting Group Concept Applied in Crosslinking of Natural Tissues with Glutaraldehyde Acetals

This work describes the results of the controlled crosslinking of collagen matrices by glutaraldehyde based on a double protection strategy, glutaraldehyde acetals and lysine protonation due to the acidic conditions of acetal formation. Materials crosslinked by this approach were characterized by thermal stability comparable to those obtained by conventional procedures with mechanical properties expected for bioprosthesis manufacture and with a higher stability toward collagenase hydrolysis. The integrity of the microfibrillar structure was confirmed by optical and scanning electronic microscopy. The results indicate that the glutaraldehyde acetals procedure may be of potential use for the crosslinking of bovine pericardium used in the manufacture of bioprosthetic devices. Advantages may be related to the production of materials with homogeneous crosslinking distributions, associated with better definition in the nature of the chemical link that they introduce, due to a better distribution of glutaraldehyde within the tissue matrix before the crosslinking reaction is allowed to occur. As a result, materials with improved biological and mechanical properties are expected.     

A群多糖脑膜炎菌苗最适免疫剂量的研究

近些年来对Ａ群多糖脑膜炎菌苗最适免疫剂量进行了一系列现场流行病学及血清学效果的对比研究。首先肯定了我国生产的菌苗与法国Ｍｅｒｉｅｕｘ研究所生产的苗苗在人体接种后观察一年内具有同等杀菌抗体反应。以后在严格对比下观察了国内生产的多糖菌苗接种３０μｇ及５０μｇ一年内的血清杀菌抗体反应。结果完全相同；而全身反应则３０μｇ为５０μｇ剂量的五分之一。在我国８０年代流脑流行地区内确证了３０μｇ免后人群保护率为９９％与国外５０μｇ的保护率（９７．２％）相似。国内连续三年在流行地区内对比观察了３０μｇ、与５０μｇ的流行病学预防效果，其人群保护率相似．与国外（Ｒｅｉｎｇｏｌｄ）．的报告亦相似。最后结论是本菌苗的最适免疫剂量为３０μｇ．不但其预防效果与５０μｇ相同，而且菌苗反应轻微，经济效益高，有利于在发展中国家推广使用。